Recent General Sarcoma News

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

(February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including... Continue Reading

Carbon Ion Beam Radiation Effective in Spinal Sarcomas

(September 6, 2013)

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of... Continue Reading

Regorafenib May Expand GIST Treatment Options

(June 13, 2012)

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical... Continue Reading

Votrient Approved for the Treatment of Sarcoma

(May 7, 2012)

The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first... Continue Reading

Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST)

(April 9, 2012)

In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal... Continue Reading

Genetic Change Linked with Rhabdomyosarcoma Survival

(April 4, 2012)

For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma... Continue Reading

FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors

(February 29, 2012)

In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better... Continue Reading

Halaven Promising in Soft-Tissue Sarcoma

(September 26, 2011)

The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which... Continue Reading

Stay on Top of Your Family History of Cancer

(July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s... Continue Reading

Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST)

(June 9, 2011)

Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). GIST... Continue Reading

Next Page »